Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide + Abiraterone + Prednisone + ADT after Docetaxel for Metastatic Prostate Cancer
NCT04267887Phase 2Active, not recruiting
- Sponsor
- OHSU Knight Cancer Institute
- Start
- May 2020
- Primary completion
- Jan 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apalutamide and Abiraterone Acetate Tablets (I) in prostate cancer (PCa), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Complete prostate specific antigen response at 12 months. Started May 2020; status: active, not recruiting.
02
Drugs
apalutamideAbiraterone Acetate Tablets (I)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04267887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267887.